Archived explainer. For the current picture see today's TRAX page.
FIRST TRACKS BIOTHER (TRAX) is up +7.73% in the latest session. Our newswire has captured 7 stories on TRAX across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
First Tracks Biotherapeutics shares rose 7.73% to $34.13 on Monday, driven by positive Phase 1b data for its lead candidate, ANB033. The stock also benefited from a wave of analyst upgrades following the release of the trial results.
First Tracks Biotherapeutics reported top-line results from Phase 1b Cohort 1 of its ANB033 trial in celiac disease. The data showed statistically significant placebo-adjusted improvements in the Vh:Cd ratio, with a value of +0.49 and a p-value of 0.009, as well as improvements in intraepithelial lymphocyte density. The company filed an 8-K with the SEC on October 13, 2026, to disclose these results.
Following the data release, several analysts raised their price targets. Canaccord Genuity lifted its target to $60 from $50 while maintaining a Buy rating. Evercore ISI Group and Wells Fargo both raised their price targets to $70, maintaining Outperform and Overweight ratings, respectively.
The stock opened at $31.17, a 1.6% gap down from the prior close of $31.68, before rallying to a session high of $34.32 at 3:55 PM ET. Trading volume reached 0.8 million shares, which is 1.0x the three-month daily average. The company has a market capitalization of $1.2 billion and remains unprofitable, with a trailing twelve-month EPS of -4.53.
The 52-week range for TRAX is $14.72 to $49.91. Over the last 8 sessions, the stock moved 1.1% from $32.99 to $33.35. Recent insider activity includes one sale totaling $1.8 million by director Ware J. Anthony in early September, with no buys recorded in the last 90 days.
Investors will monitor the upcoming Phase 1b Cohort 2 data to see if the initial positive results in celiac disease are replicated. The stock's ability to sustain its recent gains will likely depend on the consistency of these clinical outcomes.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
First Tracks Biotherapeutics offers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac disease. Read why TRAX stock is a buy.
Stock market premarket gap-ups Monday: see top movers like TRAX, CCC, XRPN & MIRM, plus what big bank earnings and inflation data mean—read now.
First Tracks Biotherapeutics reported positive top-line Phase 1b Cohort 1 results for ANB033 in celiac disease, including statistically significant placebo-adjusted improvements in Vh:Cd ratio (+0.49, p=0.009) and IEL density (-20.03, p<0.001) during a 14-day gluten challenge. Symptom measures also favored ANB033, with 47% of placebo patients versus 6% of ANB033 patients using permitted medications to manage GI symptoms. The company said ANB033 was well tolerated with no SAEs and outlined…
Filed: 2026-10-13 AccNo: 0001193125-26-419761 Size: 19 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Canaccord raises First Tracks Biotherapeutics price target on trial data
First Tracks Biotherapeutics is primarily driven by ANB033, targeting celiac disease with promising Phase 1b Cohort 1 results. See why I rate TRAX stock a hold.
More on TRAX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TRAX move explainers: 2026-10-14 · 2026-10-13